Ilumya is a biologic that was approved for the treatment of psoriasis in 2018. It is also being tested as a treatment for psoriatic arthritis.

What is Ilumya?

Ilumya (also known by its generic name tildrakizumab-asmn) was approved by the FDA in March 2018 for the treatment of moderate-to-severe plaque psoriasis in adults.

Ilumya is given by injection under the skin at weeks 0, 4, and every 12 weeks thereafter.

To learn more, please visit the Ilumya website.

FDA Approve stamp

FDA Approves Ilumya for Plaque Psoriasis

Clinical trial data show drug may help achieve clear skin.

Find out more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Get the latest news on new treatment options from NPF.

Stay up to date

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.